Peptides Dossier — citation verifiedPeptides Dossier.

Encyclopedia

Healing & repair

BPC-157

Also known as: Body Protective Compound 157, PL 14736

BPC-157 has the deepest mechanistic literature of any peptide on this site — and almost no human RCTs.
Primary sources
7

2 tier 1

Mechanism dossiers
29

21 decision

Documented cycles
4

Across all tiers

Last reviewed
2026-04-28
01·Mechanism

BPC-157 (Body Protective Compound 157) is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a fragment of human gastric juice protein, originally characterized by Predrag Sikiric's group at the University of Zagreb. The molecule is stable in gastric acid, has an approximately four-hour plasma half-life on subcutaneous injection, and is reported to produce biological effects that outlast its plasma presence — a pharmacokinetic profile consistent with the cytoprotective-mediator framing the Zagreb group has developed across three decades of rat-model work.

The mechanism story walks four converging lines of evidence across the corpus, all sourced from the same originating laboratory. The first line is angiogenesis via the VEGFR2-eNOS-NO axis: Sikiric et al. 2018, the most-cited synthesis from the Zagreb group, frames the peptide's tissue protection as routing through vascular recruitment — activating vessels to reach injury sites or opening collateral circulation when the primary route is blocked. The second line is NO-system modulation in injury repair: Klicek et al. 2008 operationalizes the NO mechanism in a colocutaneous-fistula model where BPC-157 accelerated closure across macroscopic, microscopic, and biomechanical measurements, with the L-NAME / L-arginine arms suggesting the peptide's effect is not strictly NO-dependent but interacts with the NO system rather than running solely through it. The third line is tendon fibroblast migration and musculoskeletal repair: Krivic et al. 2006 showed in a rat Achilles tendon-to-bone transection model that intraperitoneal BPC-157 restored the tendon-to-bone interface across functional, biomechanical, and immunohistochemical measurements, and substantially reversed the healing impairment produced by concurrent corticosteroid administration. The fourth line is CNS protection through the same NO-system shift: Vukojevic et al. 2020 extended the protective signal into a bilateral-carotid-clamp rat stroke model, where topical BPC-157 at 10 µg/kg preserved Morris water maze, beam-walk, and lateral-push performance, reduced hippocampal red-neuron death, and produced a transcript-level shift toward the constitutive NO-synthase isoforms (Nos3, Nos1 up; Nos2 down) alongside upregulation of Vegfr2 and the Src-Akt survival cascade. The cross-system mechanistic breadth — tendon, gastrointestinal, vascular, neurological — is the molecule's signature, and it is also the central source of academic skepticism, because broad-spectrum mechanistic claims keyed to a single short peptide are unusual in modern pharmacology.

02·Overview

BPC-157 is the peptide most readers land on first. The mechanistic rodent literature is genuinely deep across systems: tendon-to-bone repair (Krivic 2006), gastrointestinal healing and fistula closure (Klicek 2008 and the broader Sikiric program), vascular recruitment and collateral circulation (Sikiric 2018), and CNS protection in a hippocampal-ischemia stroke model (Vukojevic 2020). The cross-system rodent corpus reads like a candidate master-key for soft-tissue repair — and that breadth is precisely what produces both the biohacker enthusiasm and the academic-skeptic concern about over-claiming.

The human evidence is almost entirely anecdotal at the encyclopedia-page level. The PL 14736 / Crohn's-disease clinical development pathway that originally drove BPC-157 into pharmaceutical interest — referenced in the Klicek 2008 fistula paper's title — did not produce a peer-reviewed pivotal-trial result, and the program did not progress to FDA approval. No published placebo-controlled RCTs of BPC-157 in musculoskeletal injury or sports-medicine indications exist as of 2026. Practitioner-reported dosing patterns cluster around subcutaneous injection near the injury site in the 250–500 µg range once or twice daily for four to eight weeks; oral preparations exist and the Klicek 2008 rat model showed comparable oral and parenteral effects in that specific paradigm, but peptide oral bioavailability is a substantially harder problem in humans than in rats. There is no consensus dose because there is no human RCT to calibrate one against.

The single-laboratory concentration of the mechanistic corpus is a methodologically important caveat. The Sikiric Zagreb group has published the bulk of the world's BPC-157 literature for three decades, and independent-lab replication outside Zagreb is sparse. The 2020 Vukojevic hippocampal paper is the load-bearing post-2018 Sikiric-group mechanism paper — robust within the model, but unreplicated by an unaffiliated laboratory and conducted via a topical-bath route that does not translate directly to systemic human dosing. Mendias and Awan 2026, a Sports Medicine narrative review aimed at clinicians fielding patient questions about the gray-market peptide channel, groups BPC-157 alongside TB-500, CJC-1295, ipamorelin, MOTS-C, GHK-Cu, and SS-31 under the unapproved gray-market framing and surfaces the placebo-amplified-by-social-media dynamic as a credible-journal observation rather than an internet talking point.

The honest framing: BPC-157 has the deepest mechanistic rodent literature of any peptide on this site and one of the thinnest human evidence bases. Treat the rodent → human extrapolation with appropriate skepticism, read the source library directly rather than influencer summaries, and cross-reference the soft-tissue healing decision guide, the healing and angiogenesis dossier, and the existing critic response on theoretical pro-angiogenic concerns at /critics/bpc-157-cancer-claims.

03·Methodological caveats
04·Applied translation
05·7 primary sources

Each entry below is graded on the four-tier evidence scale (peer-primary → practitioner) and carries an independent strength label that captures how robustly the source supports the claim it backs on this page.

06·Related dossiers + decision guides

Goal-oriented comparisons and mechanism deep-dives that cover BPC-157. Decision guides compare the realistic options for a goal (peptide / drug / lifestyle); mechanism dossiers walk the pathway in depth.

Decision guides all guides →

Mechanism dossiers

07·Documented protocols — registry preview

Editorially synthesized protocols below — derived from published RCTs and practitioner case-series, each citing its source. The full registry view (all editorial patterns, all community-reported cycles, and member-logged cycles with paired biomarker deltas and adverse-event incidence aggregated at k≥5) is published to members.

Editorial protocols
2
Community-reported cycles
2
Member-logged cycles
0

  1. 01·Editorial protocol

    Achilles tendinopathy recovery

    Editorial

    Protocol

    250.0000 mcg·BID·subq

    Outcome

    4 / 5 synthesized rating

    Provenance: Editorial pattern synthesized from the Krivic 2006 rat tendon-healing study + downstream practitioner case-series. Protocol dose/duration extrapolates from the rat work; outcome ratings reflect typical practitioner-reported improvement, not direct human RCT data. · Source

  2. 02·Editorial protocol

    GI / gut barrier support (mild IBD context)

    Editorial

    Protocol

    250.0000 mcg·BID·oral

    Outcome

    3 / 5 synthesized rating

    Provenance: Editorial synthesis from Sikiric 2018 mechanistic review + the PL 14736 (Crohn-related) Phase 2 trial. Outcome rating reflects the modest-but-real signal from the only completed human GI trial. · Source

→·See the full registry

Members see 2 editorial protocols, 2 community-reported cycles, 0 consented member cycles, paired biomarker delta aggregations, and adverse-event incidence by class — all for BPC-157.

See member benefitsContribute your N=1
08·Safety

No serious adverse events have been reported in the existing literature, but the human safety record is genuinely sparse — there are no long-term human trials. Theoretical concerns include angiogenesis-driven tumor risk (any pro-angiogenic agent should be considered in this light by anyone with a personal or family history of cancer), and the standard injection-site risks of any subcutaneous peptide.

Contraindications

  • Active or past cancer (pro-angiogenic mechanism)
  • Pregnancy, breastfeeding (no data)
  • Active pelvic or abdominal infection without clinician oversight
  • Concurrent anticoagulant therapy (theoretical interaction; clinician input required)

More like this in your inbox.

The free 6-page PDF — Top 10 Peptides Worth Knowing — covers the evidence and the boundaries on the peptides every curious biohacker eventually encounters.

One unsubscribe click ends it forever. The address is never sold and never shared with vendors.

Educational only. Not medical advice. Consult a qualified clinician before any peptide use.

Last reviewed: 2026-04-28

07·Member discussion

No member discussion yet.

Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.

Become a member →Sign in